Cyclerion Therapeutics (CYCN) Change in Accured Expenses (2018 - 2025)

Cyclerion Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $85000.0 for Q3 2025.

• In Q3 2025, Change in Accured Expenses rose 140.48% year-over-year to $85000.0; the TTM figure through Sep 2025 stood at $27000.0 (up 103.21% YoY), while the FY2024 annual figure was -$515000.0, up 67.49% from the prior year.
• Change in Accured Expenses was $85000.0 for Q3 2025 at Cyclerion Therapeutics, up from -$138000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $462000.0 in Q2 2023 to a low of -$3.4 million in Q1 2021.
• Historically, Change in Accured Expenses has averaged -$362526.3 across 5 years, with a median of -$186000.0 in 2022.
• Biggest YoY gain for Change in Accured Expenses was 527.78% in 2023; the steepest drop was 636.36% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$281000.0 in 2021, then soared by 33.81% to -$186000.0 in 2022, then slumped by 97.31% to -$367000.0 in 2023, then jumped by 88.83% to -$41000.0 in 2024, then surged by 307.32% to $85000.0 in 2025.
• The last three Change in Accured Expenses figures came in at $85000.0 (Q3 2025), -$138000.0 (Q2 2025), and $121000.0 (Q1 2025), per Business Quant data.